Biological age clocks face a regulatory reckoning

Designerly’s Cooper Adwin explains why the ‘Biological Age’ metric Is threatening to derail longevity venture capital. Longevity venture capital is experiencing a breakout moment, with billions flowing into companies developing proprietary biological age clocks. Companies position epigenetic, proteomic and transcriptomic dashboards as the gold standard for measuring intervention efficacy. Yet beneath the hype lies a […] The post Biological age clocks face a regulatory reckoning appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.